Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Nevro Is Skyrocketing Today

By Brian Feroldi – Updated Apr 14, 2019 at 4:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Wall Street cheers after the company announced a surprise change in the corner office. Here's what investors need to know.

What happened

After Nevro Corp. (NVRO -1.58%), a medical device company focused on pain management, shared a number of corporate updates with investors, its shares rose 35% as of 10:55 a.m. EDT on Wednesday.

So what

Nevro announced the following corporate changes today:

  • D. Keith Grossman has been hired as the company's new President and CEO, effective immediately. He has previously held executive roles at other medical device companies called Thoratec Corporation and Conceptus, both of which were ultimately acquired. He succeeds former CEO Rami Elghandour, who was hired in 2012 and no longer has any role at the company.
  • Two new independent directors have been appointed: Elizabeth Weatherman, who is a limited partner at the private equity firm Warburg Pincus, and Kevin O'Boyle, a medical device executive with 20 years of experience. 
  • Ali Behbahani has resigned as a member of the Board.
  • Nevro is suspending its revenue guidance for the year in light of the management change.

A lot of these changes were made under the guidance of Broadfin Capital, which is a global equity healthcare manager that holds a significant amount of Nevro stock.

Check out the latest earnings call transcript for Nevro.

Businessman packing up office.

Image source: Getty Images.

Here's the commentary that Michael DeMane, Nevro's Chairman of the Board, shared with investors regarding the management change:

On behalf of the Board and our entire company, I am excited to welcome Keith Grossman to the Nevro team. Keith brings over 30 years of experience in leading innovative medical technology companies through periods of strategic change to deliver growth and enhanced value for stockholders. As we look to the future, I am confident that under Keith's direction, Nevro will be well-positioned to capture a burgeoning market opportunity with its pioneering spinal cord stimulation (SCS) technology to treat chronic pain.

Keith Grossman appears to have a successful track record of value creation behind him, so it's understandable why traders are cheering today.

Now what

Nevro has come up short of analyst estimates on its last four earnings reports, so it's understandable why the Board felt that change was necessary.

Will the new CEO be able to turbocharge the company's growth rate and create shareholder value? Only time will tell. Since leadership changes can be difficult on employees and customers, I think that caution is warranted.

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nevro Corp. Stock Quote
Nevro Corp.
NVRO
$46.60 (-1.58%) $0.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.